Drug Trial Radar · NCT05434312
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 29, 2021
Primary completion
Mar 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Peking University People's Hospital
- First posted
- Jun 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Conditions
- Chronic Myelogenous Leukemia
Interventions
TGRX-678Drug
Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximal tolerated dose (MTD)Time frame: At end of Cycle 1 (each cycle is 28 days) when the posterior probability of DLT of a dose level is higher than 33%
- Recommended phase II dose (RP2D)Time frame: At completion of the study, an average of 1.5 years
- Safety profile (DLT)Time frame: DLT: collect during Cycle 1 (28 days)
- Safety profile (AEs/SAEs)Time frame: AE and SAE: through completion of the study, an average of 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.